Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10661602 | 0.94 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL11414383 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL11418328 | 0.92 | RAB9A (0.58) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL11419008 | 0.92 | RAB9A (0.58) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL11650456 | 0.90 | TSHR (0.57) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL5253853 | 0.89 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL11257538 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL6151007 | 0.88 | RAB9A (0.58) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL3128740 | 0.88 | MEN1 (0.58) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 | |
| SCHEMBL6576043 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP19A1HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 610 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-03-15 | — | — | US | claimed |
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | AMGEN INC. | 2009-12-17 | — | — | US | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| EP-1885348-A2 | ANTIPYRETIC AGENTS AGAINST VR1-ANTAGONIST-INDUCED INCREASES IN BODY TEMPERATURE | Amgen, Inc (US) | 2008-02-13 | — | — | EP | claimed |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | AMGEN INC. | 2006-12-14 | — | — | US | claimed |
| EP-1480624-B1 | PHARMACEUTICAL TABLET | PHARMACIA CORP (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2006124753-A2 | ANTIPYRETIC AGENTS AGAINST VR1-ANTAGONIST-INDUCED INCREASES IN BODY TEMPERATURE | AMGEN INC. (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1471890-B1 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORP (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1608407-B1 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA CORP (US) | 2006-08-30 | — | — | EP | claimed |
| US-20040235803-A1 | Dispersible formulation of an anti-inflammatory agent | PHARMACIA & UPJOHN COMPANY | 2004-11-25 | — | — | US | claimed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | claimed |
| US-20040214753-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | claimed |
| WO-2004082719-A1 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004082588-A2 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235803-A1 | Dispersible formulation of an anti-inflammatory agent | TNF, LTB4R2, LTA | SMN1; SMN2 3276/4885CYP19A1 2752/4885HTT 3205/4885 |
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | SMN1; SMN2 136/4885CYP19A1 3186/4885HTT 833/4885 |
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | SMN1; SMN2 2397/4885CYP19A1 2959/4885HTT 958/4885 |
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | NIM1K, NIT2, NCL | SMN1; SMN2 136/4885CYP19A1 3186/4885HTT 833/4885 |
| US-20090312433-A1 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT | VRK1, VIPR1, AVPR1A | SMN1; SMN2 3787/4885CYP19A1 1246/4885HTT 3538/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | SMN1; SMN2 4221/4885CYP19A1 1567/4885HTT 2028/4885 |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | VRK1, VIPR1, AVPR1A | SMN1; SMN2 3787/4885CYP19A1 1246/4885HTT 3538/4885 |
| US-20040214753-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | OTC, AQP3, AQP1 | SMN1; SMN2 2371/4885CYP19A1 1271/4885HTT 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.